FDA Approves Genglycos for Glycogen Storage Disease Type Ia in Patients 8 and Older
The FDA has granted accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr) as the first treatment for GSDIa in patients aged 8 and older.
Asset / Drug
Drug and asset intelligence for Genglycos with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.